Palatin Technologies (LTS:0KF3) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0KF3 Palatin Technologies Inc LTS:0KF3
45 GF Score
Price $11.14
GF Value $51.03
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Palatin Technologies Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Palatin Technologies is: No Data: Cannot be evaluated.

Palatin Technologies  (LTS:0KF3) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Palatin Technologies Risk Assessment Related Terms

LTS:0KF3 vs BIVI, NCEL, KTTA: Risk Assessment Comparison

For the Biotechnology subindustry, Palatin Technologies's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Palatin Technologies Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palatin Technologies's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Palatin Technologies's Risk Assessment falls into.


LTS:0KF3
45GF Score
Palatin Technologies Inc LTS:0KF3
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Palatin Technologies (LTS:0KF3) Overvalued in 2026?

Based on GuruFocus' analysis, Palatin Technologies stock appears to be undervalued. The current stock price of $11.14 is trading 78.2% below its estimated GF Value™ of $51.03. GuruFocus considers Palatin Technologies to be Possible Value Trap.

Key valuation signals for LTS:0KF3:

  • Risk Assessment:
  • GF Value™: $51.03 vs. price of $11.14 (78.2% below fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the LTS:0KF3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Palatin Technologies Business Description

Other Exchanges PTN:USA
Address 103 Carnegie Center Drive, Suite 300, Princeton, NJ, USA, 08852
Palatin Technologies Inc. is a biopharmaceutical company that develops receptor-specific peptide therapeutics based on molecules that modulate the melanocortin receptor system. Its pipeline targets diseases with unmet medical needs, with programs focused on melanocortin-1 receptor (MC1R) agonists for inflammatory and dermatologic conditions and melanocortin-4 receptor (MC4R) agonists for metabolic and other indications. The company's most commercially advanced product is bremelanotide, an MC4R agonist marketed as Vyleesi for hypoactive sexual desire disorder in premenopausal women, which was approved by the FDA in 2019 and is licensed to a commercial partner in the United States. Palatin operates in a single business segment, life sciences, and generates revenue primarily through licensing fees, milestone payments, royalties, and collaboration agreements rather than direct product sales. The company is headquartered in Cranbury, New Jersey, and its activities are concentrated in the United States.
45GF Score

Get the complete analysis for LTS:0KF3

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.14
Price
$51.03
GF Value